研究者詳細 - 木下　翔太郎

Taishiro Kishimoto, Shotaro Kinoshita, Shogyoku Bun, Yasunori Sato, Momoko Kitazawa, Toshiaki Kikuchi, Mitsuhiro Sado, Akihiro Takamiya, Masaru Mimura, Takashi Nakamae, Yoshinari Abe, Tetsufumi Kanazawa, Yasuo Kawabata, Hiroaki Tomita, Koichi Abe, Akitoyo Hishimoto, Takeshi Asami, Akira Suda, Yoshinori Watanabe, Toru Amagai, Kei Sakuma, Hisashi Kida, Michitaka Funayama, Hiroshi Kimura, Aiko Sato, Shuichiro Fujiwara, Kiichiro Nagao, Naoya Sugiyama, Maki Takamiya, Hideyuki Kodama, Takaharu Azekawa, on behalf of, the, J-PROTECT collaborators

Contemporary Clinical Trials （Elsevier） 111 106596 - 106596 2021年10月

研究論文（学術雑誌）, 共著, 査読有り

INTRODUCTION: The COVID-19 pandemic has had a profound impact on the mental health of people around the world. Anxiety related to infection, stress and stigma caused by the forced changes in daily life have reportedly increased the incidence and symptoms of depression, anxiety disorder and obsessive-compulsive disorder. Under such circumstances, telepsychiatry is gaining importance and attracting a great deal of attention. However, few large pragmatic clinical trials on the use of telepsychiatry targeting multiple psychiatric disorders have been conducted to date. METHODS: The targeted study cohort will consist of adults (>18 years) who meet the DSM-5 diagnostic criteria for either (1) depressive disorders, (2) anxiety disorders, or (3) obsessive-compulsive and related disorders. Patients will be assigned in a 1:1 ratio to either a "telepsychiatry group" (at least 50% of treatments to be conducted using telemedicine, with at least one face-to-face treatment [FTF] within six months) or an "FTF group" (all treatments to be conducted FTF, with no telemedicine). Both groups will receive the usual treatment covered by public medical insurance. The study will utilize a master protocol design in that there will be primary and secondary outcomes for the entire group regardless of diagnosis, as well as the outcomes for each individual disorder group. DISCUSSION: This study will be a non-inferiority trial to test that the treatment effect of telepsychiatry is not inferior to that of FTF alone. This study will provide useful insights into the effect of the COVID-19 pandemic on the practice of psychiatry. TRIAL REGISTRATION: jRCT1030210037, Japan Registry of Clinical Trials (jRCT).

Access to Document (DOI)

Current status and challenges of the dissemination of telemedicine in Japan after the start of the COVID-19 pandemic

Shotaro Kinoshita, Taishiro Kishimoto

Telemedicine and e-Health （Mary Ann Liebert, Inc.） (in press) （ 8 ） 1220 - 1224 2021年10月

研究論文（学術雑誌）, 共著, 査読有り

Access to Document (DOI)

オンライン診療の適正な普及に関するヒアリング調査 ―現状把握と課題分析―

木下翔太郎, 成瀨浩史, 吉村健佑, 岸本泰士郎, 榎戸芙佐子, 押淵英弘, 兼子幸一, 瀬戸秀文, 辻本哲士, 長尾喜一郎, 三野進, 村田昌彦, 米田博, 稲垣中

精神神経学雑誌（日本精神神経学会） 124 （ 1 ） 16 - 27 2021年08月

研究論文（学術雑誌）, 共著, 査読有り

Camptocormia Secondary to Antipsychotic-associated Dystonia of the Rectus Abdominis Muscles Detected by Abdominal Computed Tomography

Yuki Mashima, Hiroyuki Uchida, Shotaro Kinoshita, Yuki Arita, Akira Ninomiya, Masaru Mimura, Takahito Uchida

Journal of Clinical Psychopharmacology （Ovid Technologies (Wolters Kluwer Health)） Publish Ahead of Print （ 5 ） 608 - 610 2021年07月

研究論文（学術雑誌）, 共著, 査読有り, ISSN 0271-0749

Access to Document (DOI)

遠隔医療の普及における信頼の重要性

木下翔太郎

CBEL Report （東京大学生命・医療倫理教育研究センター） 3 （ 2 ） 12 - 13 2021年02月

共著, 査読有り

Changes in Telepsychiatry Regulations during the COVID-19 Pandemic: 17 Countries and Regions' Approaches to an Evolving Healthcare Landscape

Kinoshita S., Cortright K., Crawford A., Mizuno Y., Yoshida K., Hilty D., Guinart D., Torous J., Correll C.U., Castle D.J., Rocha D., Yang Y., Xiang Y.T., Kølbæk P., Dines D., Elshami M., Jain P., Kallivayalil R., Solmi M., Favaro A., Veronese N., Seedat S., Shin S., De Pablo G.S., Chang C.H., Su K.P., Karas H., Kane J.M., Yellowlees P., Kishimoto T.

Psychological Medicine （Psychological Medicine） 52 （ 13 ） 1 - 8 2020年

研究論文（学術雑誌）, 共著, 査読有り, ISSN 00332917

Background: During the COVID-19 pandemic, the use of telemedicine as a way to reduce COVID-19 infections was noted and consequently deregulated. However, the degree of telemedicine regulation varies from country to country, which may alter the widespread use of telemediine. This study aimed to clarify the telepsychiatry regulations for each collaborating country/region before and during the COVID-19 pandemic. Methods: We used snowball sampling within a global network of international telepsychiatry experts. Thirty collaborators from 17 different countries/regions responded to a questionnaire on barriers to the use and implementation of telepsychiatric care, including policy factors such as regulations and reimbursement at the end of 2019 and as of May 2020. Results: Thirteen of 17 regions reported a relaxation of regulations due to the pandemic; consequently, all regions surveyed stated that telepsychiatry was now possible within their public healthcare systems. In some regions, restrictions on prescription medications allowed via telepsychiatry were eased, but in 11 of the 17 regions, there were still restrictions on prescribing medications via telepsychiatry. Lower insurance reimbursement amounts for telepsychiatry consultations versus in-person consultations were reevaluated in 4 regions, and consequently, in 15 regions telepsychiatry services were reimbursed at the same rate (or higher) than in-person consultations during the COVID-19 pandemic. Conclusions: Our results confirm that, due to COVID-19, the majority of countries surveyed are altering telemedicine regulations that had previously restricted the spread of telemedicine. These findings provide information that could guide future policy and regulatory decisions, that facilitate greater scale and spread of telepsychiatry globally.

Access to Document (DOI)

Tranexamic acid-induced fixed drug eruption confirmed by the drug lymphocyte transformation test.

Kenji Kawaguchi, Shotaro Kinoshita, Motonao Ishikawa, Hiroshi Sakura

Clinical case reports （John Wiley & Sons Ltd.） 7 （ 11 ） 2074 - 2075 2019年11月

研究論文（学術雑誌）, 共著, 査読有り

Access to Document (DOI)

ニボルマブ関連大腸炎に対してステロイドが有効であった転移性腎細胞がんの１例

木下翔太郎, 土岐大介, 近藤恒徳

東京女子医科大学雑誌（東京女子医科大学学会） 89 （ 2 ） 38 - 41 2019年04月

共著, 査読有り

Access to Document (DOI)

　前のページ - 次のページ　

木下 翔太郎

論文 - 木下 翔太郎

木下　翔太郎

論文 - 木下　翔太郎